Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 1996

View Archived Issues

Zeneca reveals prostaglandin antagonists

ADIR claims tachykinin antagonists

New topical corticosteroids from Hoechst

Amgen reveals polypeptide KGF analogues

Excellent preclinical results of Repel announced

Botulinum toxin type A as dermatology remedy

Positive phase III results for Phytopharm's Zemaphyte

Augmentin's new dosing/formulation cleared by FDA

Outstanding efficiency of MBI-10 series compounds

SS Pharm. reveals antibacterial quinolones

The Liposome Company's Abelcet approved in Sweden

Sankyo reports anti-HIV-1 oligodeoxyribonucleotides

Rescriptor available through Canadian expanded access program

GS-840 enters phase II/III

Additional AIDS gene therapy phase II trial

GR-92754: Most effective DHFR inhibitor

Alferon LDO enters clinical trials

Pediatric clinical trials for Remune commence

Astra reports autoimmune disease treatment agents

Generic formulation of Feldene approved

The Salk Institute for Biological Studies reveals immunophilin proteins

RPR's Taxotere available in the U.S.

Navelbine on Canadian market

ZK-138723: Schering AG's aromatase inhibitor

Actimmune metastatic renal cell carcinoma development terminated

Fujisawa reveals FR-177391, agent for cachexia in cancer patients

PN 27.1 compassionate use trial broadened

XR-9051: MDR-reversing agent

Grelan to codevelop BioNumerik's BNP-7787

Betamipron offers nephrotoxicity protection

Xalatan approved for U.S. market

Allergan's Acular available on U.K. market

Sanofi Winthrop launches tiludronic acid

Ligand/Wyeth-Ayerst collaboration extended

Phase I trial to begin for aerosolized form of osteoporosis drug

Hyperlipidemia treatment from Takeda

Monsanto reveals benzothiazepines with novel activity

ACAT inhibitors from Sankyo

Warner-Lambert seeks approval for atorvastatin

CCK-A agonists revealed by Glaxo Wellcome

rHb1.1 phase I trials begin in end-stage renal disease

SC-55494 effective in combination with rhG-CSF

EchoGen's safety and efficiency reported

Sangstat and Nextran enter marketing agreement

TpP pre-market application filed

Inerferon Sciences issued patent for potential diagnostic agent

ICD/NEO-TEST marketing agreement

Neoprobe seeks European approval for RIGScan CR49

Abbott's gonorrhea diagnostic receives marketing approval

Further ADIR research on melatonergic compounds

Compounds with melatonin receptor affinity from Takeda

5-HT2B/2C antagonists reported by SmithKline Beecham

SmithKline Beecham describes 5-HT1D antagonists

Lilly reports metabotropic glutamate receptor antagonists

Drug candidate for schizophrenia awaits clinical trials

Lithium/nimodipine combination as bipolar I manic disorder treatment

Ingenex granted phase II SBIR grant

Bristol-Myers Squibb/Garvan Institute of Medical Research collaboration

Bayer/CV Therapeutics antiinflammatory drug agreement

Exelixis acquires rights to P Element technology

HemaSure/American Red Cross Biomedical Services alliance

Lilly/Merck-Medco Managed Care diabetes program development agreement

Ascalon: Titan's newly formed subsidiary

Medeva acquires Rochester business pipeline from RPR

Xytronyx and Binary Therapeutics enter acquisition agreement

Myotrophin still pending full marketing approval

RPR's riluzole approved in Europe

Cephalon research reveals active compounds

Polypeptides with neuroprotective/neurotrophic activity

Warner-Lambert discloses complement C1r protease inhibitors

MF-8622 undergoes preclinical evaluation

XSB-1E as possible Alzheimer's treatment

More possible Alzheimer's treatment

Aspartate derivative with antiamnestic activity synthesized

Colchicine/hydroxychloroquine therapy of AD

Glutamate antagonists reported by BASF

Novo Nordisk synthesizes AMPA antagonists

More glutamate antagonists from NeuroSearch

Activase cleared by FDA for ischemic stroke

Cypros conferred SBIR grant to develop CPC-111 prodrugs

Schering-Plough seeks Nasonex approval

LTB4 antagonists from Pfizer

Sankyo reveals PAF antagonists

PDE IV inhibitor selected for further study

Endothelin antagonists from Abbott

Merck & Co. discloses endothelin antagonists

Cardiovascular disorders treatment from Boryung Pharm.

Na+/H+-exchange inhibitors from Sumitomo

More Na+/H+-exchange inhibitors from E. Merck

Selective PDGF inhibitors revealed

ITMR system phase II trial expansion granted

Antiarrhythmic agents from Merck & Co.

U.K. restriction of sotalol hydrochloride

Thrombin/trypsin inhibitors from Oscillatoria agardhii

Corvas reveals anticoagulant proteins

A02131-1: Novel PDE V inhibitor

Flomax MR approved for U.K. market

Carrington Laboratories' Aliminase enters phase III trials

5-HT4 agonists developed by Nisshin Flour Milling

Antidiabetic agents reported by Boehringer Mannheim

Troglitazone selected for NIDDK study

Aldose reductase and AGE inhibitors from Nissan Chem.

Further aldose reductase inhibitors from Sankyo

Vivus and Astra sign Muse licensing agreement

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...